ScripKriya Therapeutics, Inc. raised a $270m series C round in May 2022 with plans to take its first gene therapy candidates into the clinic in 2023. Now that the company has added more than $150m to that
ScripArbor Biotechnologies , Acrivon Therapeutics Inc. and bit.bio are the newest members of the biopharma venture capital mega-round club after the companies announced series B rounds totaling $215m, $100